Transaction #2786 · Form 4 · 0001193125-25-252404
MBX Biosciences, Inc. · Exercise / conversion · Common Stock
MBX Biosciences, Inc. · Transacted October 24, 2025 · Filed October 28, 2025
What does this filing report?
An SEC Form 4 filing for MBX Biosciences, Inc. records an exercise / conversion involving Common Stock on October 24, 2025. The reported quantity was 182,859. The filing date is October 28, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- MBX Biosciences, Inc.
- Company CIK
- 0001776111
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 182,859
- Reported price
- 3.25
- Reference value
- 594,291.75
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 664,256
- Ownership description
- Not reported
- SEC acceptance time
- Oct 28, 2025, 8:03 AM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Hawryluk P. Kent ↗
President & CEO · Director
CIK 0001673991
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- F2
- 1/48th of the shares underlying this option vest in substantially equal monthly installments on each monthly anniversary of November 7, 2022, subject to the Reporting Person's continued service on each such vesting date, until the option vests in full on November 7, 2026. The shares underlying this option became exercisable in full on November 7, 2022, pursuant to an early-exercise provision, subject to an Issuer right of repurchase.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.